BURLINGTON, Mass., Feb. 4, 2011 (GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, announced today the launch of the Acleara™ acne clearing system at the 69th Annual Meeting of the American Academy of Dermatology (AAD) in New Orleans, Louisiana, from February 5th through February 7th. The Acleara acne clearing system uses broad band light and suction to treat mild to moderate acne including acne vulgaris, comedonal and pustular acne. With the Acleara system, practitioners can treat a full face in less than 15 minutes with no numbing or cooling gels and no anesthetic costs. Acleara provides deep cleaning of pores by extracting accumulated sebaceous material, and provides targeted heating of sebaceous glands. The light activates endogenous porphyrins to destroy P. acnes and reduces sebum production through photodynamic action. According to Dr. Robert Berger, a practicing Dermatologist from Waldorf, MD and an Associate Professor of Dermatology from Johns Hopkins School of Medicine, regarding the Acleara system, "I have performed over 15,000 treatments over 5 years using a number of different technologies to treat acne. The Acleara system has proven more effective, less painful and it delivers superior results as compared to any previous technologies I have tried in treating active acne." Joseph P. Caruso, Chief Executive Officer, commented, "We are very excited about this product launch. It is a fantastic addition to our robust family of products and allows us to address the enormous acne market. The American Academy of Dermatology reports that Acne vulgaris is the most common skin condition in the United States. Up to 50 million Americans have acne and 85 percent of all U.S. teenagers have acne. The Acleara system offers physicians advanced technology to both deep clean and treat the skin." Mr. Caruso continued, "Many who suffer from acne cannot tolerate or do not want to have their acne treated by drugs. The Acleara system is an excellent alternative for consumers and physicians alike."
Attendees at the AAD Annual Meeting in New Orleans can learn about the Acleara acne clearing system at Palomar's exhibition hall booth, #811.About Palomar Medical Technologies Inc: Palomar designs, produces and sells the most advanced cosmetic lasers and intense pulsed light (IPL) systems to dramatically improve the appearance of women's and men's skin. For over 15 years, Palomar has pioneered the science of using lasers and light to improve appearances. As the industry's technology leader, Palomar has invested in creating cosmetic laser and IPL systems that put real value in the hands of physicians and other professionals to benefit consumers. Thousands of physicians worldwide trust and depend on Palomar technology to not only introduce new aesthetic treatments such as advanced laser hair removal, laser liposuction, skin resurfacing, acne, laser treatments for scars, wrinkle treatment, stretch marks (striae), and photofacials for pigmented and vascular lesions, but to also make them robust, faster, more powerful, and more comfortable for those being treated. In June 2009, Palomar became the first company to receive a 510(k) over-the-counter ("OTC") clearance from the FDA for a new, patented, home-use, laser device for the treatment of fine lines and wrinkles around the eyes (periorbital wrinkles). This OTC clearance allows Palomar to market and sell the PaloVia™ Skin Renewing Laser™ directly to consumers without a prescription. For more information on Palomar and its products, visit Palomar's website at palomarmedical.com or palovia.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of palomarmedical.com. With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2009 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT: Kerry McAnistan Investor Relations Assistant Palomar Medical Technologies, Inc. 781-993-2411 firstname.lastname@example.org